ABSTRACT
Background
In the United States, 309, 269 people were treated for end-stage renal disease (ESRD) by hemodialysis during 2004 (1) . This number of cases was a record high and almost twice the number treated just 10 years earlier (1) . Infections are the second most common cause of death among ESRD patients, and they account for nearly 14% of deaths (1) . Their risk of infection occurs as a result of immunosuppression and is exacerbated by the need to routinely access their bloodstream for treatment. Antimicrobial resistance is of particular concern because hemodialysis patients are often hospitalized, where they can be exposed to antibiotic-resistant pathogens. In addition, they are often treated with long courses of antimicrobials (2) .
The National Kidney Foundation's Kidney Disease Outcome Quality Initiative (DOQI) guidelines recom mend monitoring vascular infections to identify out breaks and observe trends (3) . CDC guidelines to prevent intravascular catheter-related infections recom mend surveillance of catheter insertion, maintenance and infection rates (4) . Local (i.e., center-specific) surveillance of infections can help identify areas where improvements in infection control might be necessary. Additionally, local surveillance data can be used to evaluate the effec tiveness of prevention interventions. If providers are to prevent antimicrobial resistance, monitoring antimicro bial use and antimicrobial resistance of organisms associ ated with infections in dialysis patients is critical (5).
Methods
CDC's National Healthcare Safety Network (NHSN) is the successor system to the Dialysis Surveillance Net work (DSN; 6), the National Nosocomial Infections Surveillance System (NNIS; 7), and the National Sur veillance System for Healthcare Workers. During 2005, outpatient hemodialysis providers already in the Dialy sis Surveillance Network transitioned into the NHSN. Dialysis surveillance activities are part of the NHSN Patient Safety Component, Device-Associated Module. The detailed protocol and case report forms are avail able at http://www.cdc.gov/ncidod/dhqp/nhsn_mem bers.html. Participants include free-standing and hospital-based centers that provide outpatient, chronic hemodialysis.
At each participating dialysis center, staff members monitor patients for any of three specific events that trigger a report: (1) an overnight hospital stay, (2) an outpatient start of an intravenous (IV) antimicrobial, or (3) a positive blood culture. More than one specific event 25 DIALYSIS SURVEILLANCE REPORT may be recorded on the same patient's report. After 20 days, the occurrence of an outpatient start of an IV antimicrobial or a positive blood culture in a patient is considered a new case; a new hospitalization can be reported at any time. The case report form captures basic clinical data for each patient and event, including the type of vascular access and use of vancomycin. Infor mation used to estimate the denominator (patient months) is obtained during the first two working days of the month. During those 2 days, the number of patients with each type of vascular access is recorded (fistula, graft, temporary and permanent central line, and port). Rates expressed in patient-months can be interpreted as the average percentage of patients having the event each month (8) .
Dialysis staff members enter this information monthly using NHSN's reporting tool, accessible through CDC's Secure Data Network. Center-specific data are immedi ately available on-line. Data aggregated from all centers are analyzed at CDC. Patient and center information is protected at CDC by provisions of federal Public Health Service law (9) .
Definitions
Each center determined whether a central line used for vascular access was considered temporary or per manent. A port vascular access was a fully implantable access device (e.g., Lifesite). We defined a hospitaliza tion as any report where a patient stayed overnight in a hospital, regardless of cause. An antimicrobial start was any initiation of a new antimicrobial agent not in use for the previous 21 days, and delivered IV. Vanco mycin starts were a subset of antimicrobial starts for which vancomycin was the agent used. We defined a local access infection as the presence of pus, redness, or swelling of the vascular access site without access-asso ciated bloodstream infection. An access-associated bloodstream infection was defined as a patient with a microorganism identified in a blood culture where the source of infection was the vascular access site. A bloodstream infection was a report of a positive blood culture, regardless of the source of the infection, and included access-associated bloodstream infections. A vascular access infection was a patient with either a local access infection or an access-associated blood stream infection.
In this report, we summarize data submitted by hemodialysis centers to the NHSN during 2006.
Results
Thirty-two centers providing outpatient hemodialysis reported data to the NHSN in 2006. These centers sub mitted data on 28,047 patient-months: 12,140 (43%) were among patients with fistulas, 8806 (31%) with per manent central lines, 6907 (25%) with grafts, 118 (0.4%) with temporary central lines, and 76 (0.3%) with ports. During 2006, dialysis centers reported 3699 adverse events. The number of events reported among patients with ports was not adequate to calculate rates or rate dis tributions. The number of events reported among patients with temporary central lines was not adequate to provide distribution of rates. Event rates varied by vascular access type ( Table 1 ). The most frequent event was hospitalization (2985 reports). The pooled mean rate of hospitalization ranged from 7.7 per 100 patientmonths among patients with fistulas to 34.7 per 100 patient-months among patients with temporary central lines. Percentiles describing the variability of rates across participating dialysis centers are also shown in Table 1 . Half of the centers had a rate of hospitalization ‡ 7.9 per 100 patient-months among patients with fistulas.
The pooled mean rate among the 977 reports of anti microbial starts ranged from 1.8 to 25.4 per 100 patientmonths. In 73% of these events, vancomycin was used; the pooled mean rate of vancomycin starts ranged from 1.2 to 16.1 per 100 patient-months. The pooled mean rate of bloodstream infection ranged from 0.5 to 27.1 per 100 patient-months. The pooled mean rate of a vas cular access infection (either a local access infection or an access-associated bloodstream infection) ranged from 0.4 to 22.9 per 100 patient-months.
Among the 532 positive blood cultures, 599 isolates were reported. Of these, 461 (77%) represented accessassociated bloodstream infections in patients with cen tral lines, and 138 (23%) were in patients with fistulas or grafts ( Table 2) . Among isolates from patients with either a central line, fistula, or graft, the microorganisms most frequently identified were common skin contami nants (e.g., coagulase-negative staphylococci). Overall, 181 isolates from positive blood cultures were tested for antimicrobial susceptibility and results reported to NHSN ( Table 3 ). The most frequently reported organ ism was S. aureus of which 42% were resistant to methi cillin (MRSA). Of the enterococci tested and reported, 26% were resistant to vancomycin.
Discussion
In 2006, rates of adverse events were higher among dialysis patients with central lines than among those with fistulas or grafts (8, 10, 11) . The rate of hospitalization among patients with temporary central lines was 34.7 per 100 patient-months, about four times the rate among those with fistulas or graphs (7.7-9.2 patients per 100 patient-months). Likewise, the rate of bloodstream infection was substantially higher among patients with temporary central lines (27.1 per 100 patient-months) than among patients with fistulas or grafts (<1 per 100 patient-months). Through the Fistula First Campaign, the Centers for Medicare and Medicaid Services (CMS), ESRD Networks, the renal community, and the Insti tute for Healthcare Improvement (IHI) are working with many other partners, including CDC, to improve the likelihood that patients receive the most optimal form of vascular access; generally an arteriovenous fis tula. Complications related to vascular access are also avoided through appropriate access monitoring and intervention (12) . However, even with optimal vascular access, careful attention to infection control is necessary to help prevent infections (13). Consistent with previous reports (8,10) we found that among bloodstream infections in patients with central lines, the most frequently reported organisms were common skin contaminants. However, among patients with fistulas or grafts, the frequency of common skin contaminants was somewhat higher in 2006 than during 1999-2005 (10). We cannot determine whether any of the common skin contaminants were true pathogens or specimen contamination (14, 15) . Antimicrobial treat ment based on a report reflecting contamination can lead to antimicrobial resistance (see http://www.cdc. gov/drugresistance/healthcare/patients.htm#dialysis).
Monitoring organisms associated with infections and their resistance patterns is necessary for prevention of resistance (5) . Methicillin-resistant Staphylococcus aureus is a major problem among patients on hemodi alysis; the rate of invasive MRSA infections in dialysis patients was an estimated 45 per 1000 in 2005 in the United States (16) . Among dialysis centers participat ing in NHSN, 42% of all S. aureus isolates from positive blood cultures were MRSA. To prevent infec tions with MRSA and other resistant organisms in out patient dialysis centers a comprehensive approach that includes prevention of infections, judicious antimi crobial use, and prevention of transmission is needed (17) .
Participation in NHSN is voluntary, and CDC restricted enrollment during 2006 to existing participants in NNIS or DSN. Therefore, results reported may not represent all U.S. centers providing outpatient hemodi alysis. Currently, all U.S. outpatient hemodialysis cen ters interested in participating in NHSN are invited to enroll. Participating centers can be free-standing dialysis centers or centers affiliated with a hospital, but they should serve mostly ambulatory, chronic hemodialysis patients. To participate in NHSN, centers must meet certain technical requirements (i.e., Internet access, a valid e-mail address, and have the ability to download a digital certificate) and make a commitment to follow the data collection protocol, complete an annual practices survey, and report data for dialysis events and denomi nator data for at least 6 months in a given year. For Dialysis centers interested in conducting surveillance for adverse events often ask about the time and resource investment surveillance activities require. A hospitalbased unit serving dialysis outpatients recently documented implementation of surveillance activities using the NHSN protocol (18) . In their experience, the methods were easy to implement; maintenance of the activities required an estimated 2 hours of staff time per month. The facility observed that surveillance participa tion resulted in a decline in rates of bloodstream infec tions and antimicrobial use through ownership and engagement of staff (18) .
The National Healthcare Safety Network provides tools for outpatient dialysis centers to analyze their own data so that they can monitor trends, evaluate needs for prevention, and measure the impact of their prevention efforts. Adjusting the number of events for patient risk factors, such as vascular access type, and the time period at risk is needed to compare rates across dialysis centers. The dialysis surveillance activities in the NHSN use patient-months as the adjustment for time at risk, but other methods are available and rates can be converted for comparability (19) . For further information about surveillance and the prevention of dialysis-associated adverse events, please visit http://www.cdc.gov/ncidod/ dhqp/dpac_dialysis_pc.html.
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